TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Belief in opioid addiction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discussion of personal experience with medication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: enhancing physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of coagulation activation and fibrinolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exposure in paediatric patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective effects of cocaine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of complete epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing within 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate to Panitumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to scheduled appointments
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Pain experienced during probe insertion, biopsy, and 30 minutes after biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient procedure‐related overall satisfaction level
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Opioid consumption in 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain after movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTP (Pharyngeal Pressure) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk for pelvic floor surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acceptance of the law of presumed consent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Interest in attending a talk about ODT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patient physical symptom distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pulse oximeter perfusion index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sympathectomy‐mediated vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: intensity of motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost-effectiveness of sildenafil treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Favorable clinical response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance checklist scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in global clinical behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Health Assessment Questionnaire/Health Assessment Questionnaire disability index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: functional aerobic impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality within the first 3 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Satisfactory control of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new Q-wave MI
Endpoint domain: Mortality/survival
Primary endpoint: Total adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vigilance deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BAT-specific energy expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-body energy expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in acne lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score of global acne grading system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of acne flare during treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Mitral deceleration time (DT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual field progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bone Probing Depth (BPD)
Endpoint domain: Physiological/clinical
Primary endpoint: Probing Depth (PD)
Endpoint domain: Physiological/clinical
Primary endpoint: SIA (Surgically Induced Astigmatism)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Postoperative astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: UCVA (Uncorrected Visual Acuity) of 20/32 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Underestimation of cognitive abilities during hypoglycaemia
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Arterial stiffness (baPWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean onset time of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of action of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increases in blood pressure and heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of pin-site complications
Endpoint domain: Adverse events/effects
Primary endpoint: full-scale IQ score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: verbal IQ score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: performance IQ score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: BCAA valine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BCAA leucine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute Myocardial Infarction (AMI)
Endpoint domain: Mortality/survival
Primary endpoint: 5-minute Apgar score < 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal intensive care admission
Endpoint domain: Adverse events/effects
Primary endpoint: Average TOVA ADHD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTRS ADHD index T scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPRS ADHD index T scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean completion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean angular path length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean path length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bathing completeness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum adalimumab levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiadalimumab ADAbs presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft failure attributable to rejection
Endpoint domain: Mortality/survival
Primary endpoint: definite rejection episode
Endpoint domain: Mortality/survival
Primary endpoint: aortic systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fasting plasma glucose (FHG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Drug delivery accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects free from device‐related serious adverse events (DRSAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: P sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death of unknown causes
Endpoint domain: Mortality/survival
Primary endpoint: Deep-vein thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Total daily symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Systolic blood pressure reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic blood pressure reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of systolic hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain scores immediately after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in daily cigarette smoking by 50% or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent time within the target SpO2 range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent time spent below the target or in hypoxemia (SpO2 <80%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent time spent above the target range or at extreme hyperoxemia (SpO2 >98%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of health care‐associated infections
Endpoint domain: Adverse events/effects
Primary endpoint: Normoglycemia achievement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of lung function decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients fulfilling criteria for MDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative LA PCEA bolus volumes until day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LA consumption volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Composite Score (MCS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of dyskinesia
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of dyskinesia
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of artificial enamel lesion formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute dysphagia, odynophagia and pain
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of late mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: mean trough FEV1 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: vertebral body wedge deformity restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extracanal leakage rate
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of cycles with low response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with ovum retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uIGF-I/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total BDI‐IA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS Parts I score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS Parts II score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV DNA levels below 1000 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy on paired associates learning task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy on reversal learning task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy on delayed pattern recognition task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean numbers of intraoperative AAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to last observable AAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients free of AAL at days 3 and 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distress as measured by FSDS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: angiographic in-segment late lumen loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: duration of drains
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: lag time for LDL oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma and LDL all-trans beta-carotene levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased explicit fat bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adrenal suppression measured by overnight urinary cortisol/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urinary cortisol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: disease-specific overall five-year survival
Endpoint domain: Mortality/survival
Primary endpoint: median disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: median time to recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of stone cannulation (SC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief measured by visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence rate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean difference between efavirenz DBS-predicted concentrations and measured plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of soluble CD14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: proportions of tissue factor-positive patrolling monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Alcohol abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-first relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative abstinence at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall estimated survival
Endpoint domain: Mortality/survival
Primary endpoint: Development of adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Hearing aid self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of hearing aids
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Readiness for hearing rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in ultrasound parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of pressure sore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h volume of exudates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound-bed tissue type
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from AF or AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QFG‐IT test positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Efficiency at emptying the bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Overall satisfaction with the catheter
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SCL-90 total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6, CRP and Lac levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Child's global health improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fT4 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Infection detection accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change of symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of miscarriage
Endpoint domain: Mortality/survival
Primary endpoint: flare-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flare experience
Endpoint domain: Adverse events/effects
Primary endpoint: Mean numbers of packed erythrocyte transfusions per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean reticulocyte counts at the sixth week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: composite risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum IMA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum cTnI level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of complicated ventricular arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total IV narcotic usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of 50% histamine release
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of asthenic and cognitive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response rate defined as improvement of >30% in CAPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet-monocyte conjugation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Caspase-3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PARP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bcl-2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Knowledge scores of drug use
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Drug misuse and abuse prevention behavior scores
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Reduction in seated trough SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prolactin reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Average postprandial blood glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of youth victimization
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of youth perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Depression levels in youth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General feeling of illness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduced productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: period of disablement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reliability of velocity measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: life-years with obesity averted
Endpoint domain: Mortality/survival
Primary endpoint: cases of obesity averted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk for acute ankle injury
Endpoint domain: Adverse events/effects
Primary endpoint: risk of upper-extremity injuries
Endpoint domain: Adverse events/effects
Primary endpoint: time loss due to injuries
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ACT score for uncontrolled asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean BP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pulse pressure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variability in weight readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of alerts generated to the telemonitoring system
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: VAS pain score on movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Right upper-limb range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left upper-limb range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study completion rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention